CompletedPhase 3

Genotropin Study Assessing Use of Injection Pen

United States136 participantsStarted 2009-10

Plain-language summary

Assessment of Genotropin patient and caregiver (Dyad) perception of convenience and preference of Genotropin injection pen. Patients already on genotropin will be asked to use a genotropin pen for 2 months. Patient and caregiver will be asked to complete a questionnaire at baseline and 2 months.

Who can participate

Age range8 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 8-18 years * Using genotropin pen for at least 3 months prior to study enrollment * Compliance with genotropin treatment Exclusion Criteria: * Medical conditions that can affect participation in study * Insufficient command of English language to understand questionnaire * Using other growth hormone device and not Genotropin pen

What they're measuring

Percentage of Dyads (Participant and Caregiver or Parent) Reporting no Difference or Easier to Use for New Genotropin Mark VII Injection Pen Compared to Pre-study Experience With the Genotropin Pen®

Timeframe: 2 months

Trial details

NCT IDNCT00965484

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-01

Results submitted2010-12-02

View on ClinicalTrials.gov More Growth Hormone Deficiency trials